Trying 11180...Open

PLEASE ENTER HOST PORT ID:
PLEASE ENTER HOST PORT ID:x
LOGINID:d180mxt
PASSWORD:
TERMINAL (ENTER 1, 2, 3, 4, OR ?): 3

```
 ********************************
 *                              *
 *      Welcome to MESSENGER (APS Text) at USPTO      *
 *                              *
 *                              *
 *  The USPTO production files are current through:    *
 *  MARCH 23,1999  for U.S. Patent Text Data.          *
 *  MARCH 23,1999  for U.S. Current Classification Data. *
 *  MARCH 23,1999  for U.S. Patent Image Data.         *
 *                              *
 ********************************
  AFTER PRODUCTION HOURS (AT 10:00 P.M.) ON WEDNESDAY,
01/27/99,
  SEVERAL PTONET DEVICES WILL BE RECONFIGURED TO ENHANCE
NETWORK OPERATIONS.  USERS OF PATENT EXAMINER SEARCH
TOOLS
  MUST RE-BOOT THEIR INDIVIDUAL DESKTOP WORKSTATIONS AT THE
  START OF THE BUSINESS DAY ON THURSDAY, 01/28/99 TO INSURE
  THAT NECESSARY FILES ON THEIR WORKSTATION GET UPDATED.
THIS
  WILL ENSURE IMMEDIATE AND ACCURATE ACCESS TO ALL OF THE
  PATENT EXAMINER SEARCH TOOLS.  THANK YOU FOR YOUR
COOPERATION
 ********************************
 *    * PLEASE USE 305-9000 FOR NEW TELEPHONE NUMBER *    *
 *                              *
 ********************************
 * More U.S. patent data is now available on APS.  The new    *
 * USOCR file contains patents issued in 1970, plus some      *
 * patents that were missing from the USPAT file.  See the    *
 * Patents News Folder under the Public Folders in e-mail for *
 * more information on using the new file.  Thank you.        *
 ********************************
 * DISCLAIMER:                  *
 * Neither the United States Government, nor any agency       *
 * thereof, nor any of their contractors, subcontractors or   *
 * employees make any warranty, expressed or implied,         *
 * including any warranty of marketability of fitness for a   *
 * particular purpose; nor assumes any legal liability or     *
 * responsibility for any party's use, or the results of      *
 * such, of the data.           *
 ********************************
 *          Help Desk --> 703-305-9000          *
 *                              *
 *  The Help Desk is staffed for APS support 7 days/week.     *
 *    Monday through Friday:    6:30am - 9:00pm               *
 *    Saturday, Sunday, Holidays: 8:30am - 5:00 pm            *
 *                              *
 *  The Help Desk staff at this number will handle all APS    *
 *  related questions.          *
 ********************************
 *  >>>>>>>>>>>>> NEW SUNDAY HOURS !!! <<<<<<<<<<<<<<        *
 *                              *
 *  The APS is available:       *
 *       6:30am - 9:00pm Monday through Friday                *
 *       7:30am - 5:00pm Saturday, Sunday, Holidays           *
 *                              *
 *   APS is unavailable Thanksgiving Day, Christmas Day,      *
 *   and New Year's Day.        *
 *                              *
 ********************************
FILE 'USPAT' ENTERED AT 15:02:01 ON 25 MAR 1999

 ********************************
 *       WELCOME TO THE         *
 *    U.S. PATENT TEXT FILE     *
 ********************************
```

=> e goodwin, raymond/in

E#	FILE	FREQUENCY	TERM
E1	USPAT	2	GOODWIN, RAY/IN
E2	USPAT	1	GOODWIN, RAY R/IN
E3	USPAT	2 -->	GOODWIN, RAYMOND/IN
E4	USPAT	19	GOODWIN, RAYMOND G/IN
E5	USPAT	3	GOODWIN, RAYMOND W/IN
E6	USPAT	1	GOODWIN, RAYMOND WENDELL/IN
E7	USPAT	1	GOODWIN, RCHARD H JR/IN
E8	USPAT	1	GOODWIN, RICHARD/IN
E9	USPAT	1	GOODWIN, RICHARD A/IN
E10	USPAT	1	GOODWIN, RICHARD B/IN
E11	USPAT	1	GOODWIN, RICHARD H/IN
E12	USPAT	4	GOODWIN, RICHARD H JR/IN

=> s e1 or e3 or e4

        2 "GOODWIN, RAY"/IN
        2 "GOODWIN, RAYMOND"/IN
       19 "GOODWIN, RAYMOND G"/IN
COMMAND INTERRUPTED

=> s e1 or e3 or e4

        2 "GOODWIN, RAY"/IN
        2 "GOODWIN, RAYMOND"/IN
       19 "GOODWIN, RAYMOND G"/IN
COMMAND INTERRUPTED
YOU HAVE RECEIVED THIS ERROR MESSAGE 2 CONSECUTIVE TIMES
If this message appears repeatedly, or for further help, please
contact your Help Desk.
IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP
DESK
=> s e1 or e3 or e4

        2 "GOODWIN, RAY"/IN
        2 "GOODWIN, RAYMOND"/IN
       19 "GOODWIN, RAYMOND G"/IN
L1   23 "GOODWIN, RAY"/IN OR "GOODWIN, RAYMOND"/IN OR
"GOODWIN, RAY
MON
         D G"/IN

=> s fas(w)ligand

      662 FAS
       12 FASES
      674 FAS
          (FAS OR FASES)
    21575 LIGAND
    17340 LIGANDS
    26872 LIGAND
          (LIGAND OR LIGANDS)
L2   28 FAS(W)LIGAND

=> s l1 and l2

L3   1 L1 AND L2

=> d l3 leg ab

US PAT NO: 5,763,223 [IMAGE AVAILABLE] L3: 1 of 1
DATE ISSUED: Jun. 9, 1998
TITLE: DNA encoding a cytokine that induces apoptosis
INVENTOR: Steven R. Wiley, Seattle, WA
           Raymond G. Goodwin, Seattle, WA
ASSIGNEE: Immunex Corporation, Seatlle, WA (U.S. corp.)
APPL-NO: 08/670,354
DATE FILED: Jun. 25, 1996
ART-UNIT: 182
PRIM-EXMR: John Ulm
ASST-EXMR: Prema Mertz
LEGAL-REP: Kathryn A. Anderson

US PAT NO: 5,763,223 [IMAGE AVAILABLE] L3: 1 of 1

ABSTRACT:
A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.

=> d l3 kwic

US PAT NO: 5,763,223 [IMAGE AVAILABLE] L3: 1 of 1
INVENTOR: Steven R. Wiley, Seattle, WA
           Raymond G. Goodwin, Seattle, WA

SUMMARY:

BSUM(4)

DNAs encoding a rat **Fas ligand** (Suda et al., Cell, 75:1169, 1993) and a human **Fas ligand** (Takahashi et al., International Immunology 6:1567, 1994) have been isolated. Binding of the **Fas ligand** to cells expressing Fas antigen has been demonstrated to induce apoptosis (Suda et al., supra, and Takahashi et al., supra).

DETDESC:

DETD(11)

The TRAIL of the present invention is distinct from the protein known as **Fas ligand** (Suda et al., Cell, 75:1169, 1993; Takahashi et al., International Immunology 6:1567, 1994). **Fas ligand** induces apoptosis of certain cell types, via the receptor known as Fas. As demonstrated in example 5, TRAIL-induced apoptosis of. . . mediated through Fas. The human TRAIL amino acid sequence of SEQ ID NO:2 is about 20% identical to the human **Fas ligand** amino acid sequence that is presented in Takahashi et al., supra. The extracellular domain of human TRAIL is about 28.4% identical to the extracellular domain of human **Fas ligand**.

DETDESC:

DETD(12)

The . . . and the amino acid sequence of the extracellular domain of other proteins of this family are as follows: 28.4% with **Fas ligand**, 22.4% with lymphotoxin-.beta., 22.9% with TNF-.beta., 23.1% with TNF-.beta., 22.1% with CD30 ligand, and 23.4% with CD40 ligand.

DETDESC:

DETD(121)

Thus, a patient may be treated with an agent that inhibits **Fas-ligand**-mediated apoptosis of endothelial cells, in combination with an agent that inhibits TRAIL-mediated apoptosis of endothelial cells. In one embodiment, an. . .

DETDESC:

DETD(159)

Jurkat . . . a 6 well plate with 2.5 mls of media with various combinations of fixed cells, supernatants from cells transfected with **Fas ligand**, and various antibodies, as indicated below.

DETDESC:

DETD(163)

DNA laddering was also seen when Jurkat cells were co-cultured with concentrated supernatants from COS cells transfected with DNA encoding human **Fas ligand** in pDC409. The supernatants are believed to contain soluble **Fas ligand** that is proteolytically released from

the cell surface. The Fas ligand-induced DNA laddering could be blocked by adding 10 .mu.g/ml of a soluble blocking monoclonal antibody directed against Fas. This same. . .

DETDESC:

DETD(183)

Jurkat . . . 37.degree. C., after which wells were aspirated and washed twice with PBS to remove unbound antibody. Jurkat cells treated with Fas ligand or M3, a blocking monoclonal antibody directed against Fas, (Alderson et al., J. Exp. Med. 181:71, 1995; and PCT application. . .

DETDESC:

DETD(187)

Fas ligand demonstrated the ability to kill Jurkat cells. The anti-Fas antibody M3 inhibited the activity of Fas ligand, but not the activity of TRAIL.

d his

(FILE 'USPAT' ENTERED AT 15:02:01 ON 25 MAR 1999)
E GOODWIN, RAYMOND/IN
L1 23 S E1 OR E3 OR E4
L2 28 S FAS(W)LIGAND
L3 1 S L1 AND L2

=> d l2 1-28 leg ab

US PAT NO: 5,885,827 [IMAGE AVAILABLE] L2: 1 of 28
DATE ISSUED: Mar. 23, 1999
TITLE: Eukaryotic high rate mutagenesis system
INVENTOR: Matthias Wabl, San Francisco, CA
Jurgen Bachl, San Francisco, CA
ASSIGNEE: The Regents of the Universtiy of California, Oakland, CA (U.S. corp.)
APPL-NO: 08/589,112
DATE FILED: Jan. 23, 1996
ART-UNIT: 166
PRIM-EXMR: James Ketter
ASST-EXMR: Irem Yucel
LEGAL-REP: Cooley Godward LLP

US PAT NO: 5,885,827 [IMAGE AVAILABLE] L2: 1 of 28

ABSTRACT:
A method is provided for performing saturation mutagenesis on a target gene by exploiting the immunoglobulin hypermutation system. A target gene is cloned into an expression vector containing immunoglobulin enhancer fragments that effect hypermutation, and this construct is then transfected into an immunoglobulin mutator cell, typically of pre-B lymphocyte lineage. The target gene is permitted to hypermutate at a rate approaching that of 10.sup.-4 /bp/generation as the cells are cultured to a desired density. The variant polypeptides encoded by the hypermutated target gene can then be selected.

US PAT NO: 5,877,285 [IMAGE AVAILABLE] L2: 2 of 28
DATE ISSUED: Mar. 2, 1999
TITLE: Mammalian thymokine having leukocyte chemotactic activity, and fragments thereof
INVENTOR: Gregory S. Kelner, Cupertino, CA
Jacqueline L. Kennedy, Sunnyvale, CA
Albert Zlotnik, Palo Alto, CA
ASSIGNEE: Schering Corporation, Kenilworth, NJ (U.S. corp.)
APPL-NO: 08/472,604
DATE FILED: Jun. 7, 1995
ART-UNIT: 166
PRIM-EXMR: Lorraine Spector
LEGAL-REP: Kenneth A. Weber, Edwin P. Ching

US PAT NO: 5,877,285 [IMAGE AVAILABLE] L2: 2 of 28

ABSTRACT:
Nucleic acids encoding a thymokine from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.

US PAT NO: 5,876,939 [IMAGE AVAILABLE] L2: 3 of 28
DATE ISSUED: Mar. 2, 1999
TITLE: FAS associated proteins
INVENTOR: John C. Reed, Carlsbad, CA
Takaaki Sato, San Diego, CA
ASSIGNEE: La Jolla Cancer Research Foundation, La Jolla, CA (U.S. corp.)
APPL-NO: 08/858,311
DATE FILED: May 19, 1997
ART-UNIT: 164
PRIM-EXMR: Kenneth R. Horlick
LEGAL-REP: Campbell & Flores LLP

US PAT NO: 5,876,939 [IMAGE AVAILABLE] L2: 3 of 28

ABSTRACT:
The present invention provides mammalian protein tyrosine phosphatases, human PTP-BAS type 4, human PTP-BAS type 5a and mouse PTP-BAS type 5b,
each of which is a Fas-associated protein (FAP), nucleic acid molecules encoding a PTP-BAS type 4 or a PTP-BAS type 5 and antibodies specific for a PTP-BAS type 4 or for a PTP-BAS type 5. The invention also provides methods for identifying FAP's, which can associate with Fas and can modulate apoptosis. The invention also provides screening assays for identifying an agent that can effectively alter the association of a FAP with Fas and, therefore, can increase or decrease the level of apoptosis in a cell. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a PTP-BAS or fragment of a PTP-BAS or an antisense nucleotide sequence, which is complementary to a portion of a nucleic acid molecule encoding a PTP-BAS. The invention also provides a method of using a reagent that can specifically bind to a FAP to diagnose a pathology that is characterized by an increased or decreased level of apoptosis in a cell. The invention also provides methods of modulating apoptosis in a cell by contacting the cell with an agent that effectively alters the association of a FAP and Fas in a cell or alters the activity of a FAP in a cell.

US PAT NO: 5,858,990 [IMAGE AVAILABLE] L2: 4 of 28
DATE ISSUED: Jan. 12, 1999
TITLE: Fas ligand compositions for treatment of proliferative disorders
INVENTOR: Kenneth Walsh, Carlisle, MA
ASSIGNEE: St. Elizabeth's Medical Center, Boston, MA (U.S. corp.)
APPL-NO: 08/810,453
DATE FILED: Mar. 4, 1997
ART-UNIT: 165
PRIM-EXMR: George C. Elliott
ASST-EXMR: Sean McGarry
LEGAL-REP: Wolf, Greenfield & Sacks, P.C.

US PAT NO: 5,858,990 [IMAGE AVAILABLE] L2: 4 of 28

ABSTRACT:
A method for treating vascular injury, particularly vascular injury resulting from restenosis following angioplasty, and vascular remodeling is provided. The method involves administering to subjects in need of such treatment an effective amount of a Fas ligand molecule.

US PAT NO: 5,854,043 [IMAGE AVAILABLE] L2: 5 of 28
DATE ISSUED: Dec. 29, 1998
TITLE: MEKK-related signal transduction kinases
INVENTOR: Gary L. Johnson, Boulder, CO
ASSIGNEE: National Jewish Center for Immunology and Respiratory Medicine, Denver, CO (U.S. corp.)
APPL-NO: 08/323,460
DATE FILED: Oct. 14, 1994
ART-UNIT: 166
PRIM-EXMR: Sally P. Teng
LEGAL-REP: Giulio A. DeConti, Jr., Catherine J. Kara

US PAT NO: 5,854,043 [IMAGE AVAILABLE] L2: 5 of 28

ABSTRACT:
The present invention relates to isolated MEKK proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to use such proteins to regulate signal transduction in a cell. The present invention also includes therapeutic compositions comprising such proteins or nucleic acid molecules that encode such proteins and their use to treat animals having medical disorders including cancer, inflammation, neurological disorders, autoimmune diseases, allergic reactions, and hormone-related diseases. When MEKK is expressed, it phosphorylates and activates MEKs including MEK-1, MEK-2 and JEK.

US PAT NO: 5,851,806 [IMAGE AVAILABLE] L2: 6 of 28
DATE ISSUED: Dec. 22, 1998
TITLE: Complementary adenoviral systems and cell lines
INVENTOR: Imre Kovesdi, Rockville, MD
Douglas E. Brough, Olney, MD
Duncan L. McVey, Derwood, MD
Joseph T. Bruder, Gaithersburg, MD
Alena Lizonova, Rockville, MD
ASSIGNEE: GenVec, Inc., Rockville, MD (U.S. corp.)
APPL-NO: 08/572,126
DATE FILED: Dec. 14, 1995
ART-UNIT: 185
PRIM-EXMR: David Guzo
ASST-EXMR: William Sandals
LEGAL-REP: Leydig, Voit & Mayer, Ltd.

US PAT NO: 5,851,806 [IMAGE AVAILABLE] L2: 6 of 28

ABSTRACT:
The present invention provides multiply replication deficient adenoviral vectors having a spacer in at least one replication deficient adenoviral region, as well as complementing cell lines therefor. Also provided are means of constructing the multiply replication deficient adenoviral vectors and methods of use thereof, e.g., in gene therapy.

US PAT NO: 5,851,782 [IMAGE AVAILABLE] L2: 7 of 28
DATE ISSUED: Dec. 22, 1998
TITLE: Inhibitors of ceramidase
INVENTOR: Yusuf A. Hannun, Chapel Hill, NC
Alicja Bielawska, Apex, NC
Charles McKay, Wilmington, DE
ASSIGNEE: Duke University, Durham, NC (U.S. corp.)
APPL-NO: 08/745,128
DATE FILED: Nov. 8, 1996
ART-UNIT: 161
PRIM-EXMR: Richard L. Raymond
LEGAL-REP: Nixon & Vanderhye P.C.

US PAT NO: 5,851,782 [IMAGE AVAILABLE] L2: 7 of 28

ABSTRACT:
The present invention relates, in general, to the bioeffector molecule ceramide and, in particular, to methods of effecting intracellular accumulation of ceramide. The invention further relates to methods of selecting compounds that inhibit alkaline ceramidase and that can be used to treat diseases/disorders associated with cell hyperplasia or dedifferentiation.

US PAT NO: 5,830,916 [IMAGE AVAILABLE] L2: 8 of 28
DATE ISSUED: Nov. 3, 1998
TITLE: Inhibitor of ceramidase
INVENTOR: Yusuf A. Hannun, Chapel Hill, NC
Alicja Bielawska, Apex, NC
Charles McKay, Durham, NC
ASSIGNEE: Duke University, Durham, NC (U.S. corp.)
APPL-NO: 08/652,238

DATE FILED: May 23, 1996
ART-UNIT: 129
PRIM-EXMR: Richard L. Raymond
LEGAL-REP: Nixon & Vanderhye P.C.

US PAT NO: 5,830,916 [IMAGE AVAILABLE] L2: 8 of 28

ABSTRACT:
The present invention relates, in general, to the bioeffector molecule ceramide and, in particular, to methods of effecting intracellular accumulation of ceramide. The invention further relates to methods of selecting compounds that inhibit alkaline ceramidase and that can be used to treat diseases/disorders associated with cell hyperplasia or dedifferentiation.

US PAT NO: 5,830,469 [IMAGE AVAILABLE] L2: 9 of 28
DATE ISSUED: Nov. 3, 1998
TITLE: Fas antagonists and uses thereof
INVENTOR: David H. Lynch, Bainbridge Island, WA
Mark R. Alderson, Bainbridge Island, WA
ASSIGNEE: Immunex Corporation, Seattle, WA (U.S. corp.)
APPL-NO: 08/429,499
DATE FILED: Apr. 26, 1995
ART-UNIT: 182
PRIM-EXMR: Susan A. Loring
LEGAL-REP: Kathryn A. Anderson

US PAT NO: 5,830,469 [IMAGE AVAILABLE] L2: 9 of 28

ABSTRACT:
The present invention provides a panel of monoclonal antibodies and binding proteins which specifically bind to human Fas antigen. Some of the antibodies and binding proteins are capable of stimulating T cell proliferation, inhibiting binding of anti-Fas CH-11 monoclonal antibody to cells expressing Fas antigen, blocking anti-Fas CH-11 monoclonal antibody-mediated lysis of cells, and blocking Fas ligand-mediated lysis of cells. The invention also provides for therapeutic compositions comprising the monoclonal antibodies.

US PAT NO: 5,830,463 [IMAGE AVAILABLE] L2: 10 of 28
DATE ISSUED: Nov. 3, 1998
TITLE: Yeast-based delivery vehicles
INVENTOR: Richard C. Duke, Denver, CO
Alex Franzusoff, Boulder, CO
Donald Bellgrau, Denver, CO
ASSIGNEE: University Technology Corporation, Boulder, CO (U.S. corp.)
APPL-NO: 08/340,185
DATE FILED: Nov. 15, 1994
ART-UNIT: 162
PRIM-EXMR: Jasemine C. Chambers
ASST-EXMR: Karen M. Hauda
LEGAL-REP: Sheridan Ross P.C.

US PAT NO: 5,830,463 [IMAGE AVAILABLE] L2: 10 of 28

ABSTRACT:
The present invention includes yeast vehicles and their use as delivery vehicles. Yeast vehicles include a yeast portion and a heterologous compound. Such yeast vehicles can be used to protect animals from disease and to otherwise carry compounds to given cell types. Examples of yeast vehicles include gene delivery vehicles, drug delivery vehicles, and immunomodulatory vehicles. Immunomodulatory vehicles are capable of modulating an immune response. When stimulating an immune response, such yeast vehicles effect cell-mediated as well as humoral immunity.

US PAT NO: 5,786,210 [IMAGE AVAILABLE] L2: 11 of 28
DATE ISSUED: Jul. 28, 1998
TITLE: Mammalian thymokine genes
INVENTOR: Gregory S. Kelner, Cupertino, CA
Jacqueline L. Kennedy, Sunnyvale, CA
Albert Zlotnik, Palo Alto, CA
ASSIGNEE: Schering Corporation, Kenilworth, NJ (U.S. corp.)
APPL-NO: 08/329,704
DATE FILED: Oct. 25, 1994
ART-UNIT: 182
PRIM-EXMR: Stephen Walsh
ASST-EXMR: Lorraine Spector
LEGAL-REP: Jonathan A. Quine, Kenneth A. Weber, Edwin P. Ching

US PAT NO: 5,786,210 [IMAGE AVAILABLE] L2: 11 of 28

ABSTRACT:
Nucleic acids encoding a thymokine from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.

US PAT NO: 5,770,690 [IMAGE AVAILABLE] L2: 12 of 28
DATE ISSUED: Jun. 23, 1998
TITLE: Bax omega protein and methods
INVENTOR: Catherine Mastroni Bitler, Menlo Park, CA
Stephen Scott Bowersox, Menlo Park, CA
Roberto Crea, San Mateo, CA
Susan Dunham Demo, San Francisco, CA
William A. Horne, San Diego, CA
Mei Zhou, Palo Alto, CA
ASSIGNEE: Neurex Corporation, Menlo Park, CA (U.S. corp.)
APPL-NO: 08/616,732
DATE FILED: Mar. 15, 1996
ART-UNIT: 185
PRIM-EXMR: James Ketter
ASST-EXMR: Irem Yucel
LEGAL-REP: Charles K. Sholtz, Peter J. Dehlinger.

US PAT NO: 5,770,690 [IMAGE AVAILABLE] L2: 12 of 28

ABSTRACT:
Bax-.omega. polynucleotides and polypeptides, and compositions effective to hybridize to Bax-.omega. polynucleotides are disclosed. Also disclosed are methods for altering apoptosis in cells, for promoting cell survival and for identifying compounds capable of affecting the binding of Bax-.omega. to other proteins involved in apoptosis.

US PAT NO: 5,770,383 [IMAGE AVAILABLE] L2: 13 of 28
DATE ISSUED: Jun. 23, 1998
TITLE: Tricyclic retinoids, methods for their production and use
INVENTOR: Chan Kou Hwang, Boulder, CO
Steven K. White, San Diego, CA
Youssef L. Bennani, La Jolla, CA
Stacie S. Canan Koch, San Diego, CA
Beth Ann Badea, San Diego, CA
Jonathan J. Hebert, Mission Viejo, CA
Luc J. Farmer, La Jolla, CA
Alex M. Nadzan, San Diego, CA
ASSIGNEE: Ligand Pharmaceuticals, Inc., San Diego, CA (U.S. corp.)
APPL-NO: 08/475,397
DATE FILED: Jun. 7, 1995
ART-UNIT: 168
PRIM-EXMR: Ponnathapura Achutamurthy
LEGAL-REP: William L. Respess, J. Scott Elmer

US PAT NO: 5,770,383 [IMAGE AVAILABLE] L2: 13 of 28

ABSTRACT:
Tricyclic retinoids having activity for retinoic acid receptors and/or retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such tricyclic retinoid compounds and methods for their therapeutic use.

US PAT NO: 5,770,382 [IMAGE AVAILABLE] L2: 14 of 28
DATE ISSUED: Jun. 23, 1998
TITLE: Tricyclic retinoids, methods for their production and use
INVENTOR: Chan Kou Hwang, Boulder, CO
Steven K. White, San Diego, CA
Beth Ann Badea, San Diego, CA
Alex M. Nadzan, San Diego, CA
ASSIGNEE: Ligand Pharmaceuticals, Inc., San Diego, CA (U.S. corp.)
APPL-NO: 08/475,514
DATE FILED: Jun. 7, 1995
ART-UNIT: 168
PRIM-EXMR: Ponnathapura Achutamurthy
LEGAL-REP: William L. Respess, J. Scott Elmer

US PAT NO: 5,770,382 [IMAGE AVAILABLE] L2: 14 of 28

ABSTRACT:
Tricyclic retinoids having activity for retinoic acid receptors and/or retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such tricyclic retinoid compounds and methods for their therapeutic use.

US PAT NO: 5,770,378 [IMAGE AVAILABLE] L2: 15 of 28
DATE ISSUED: Jun. 23, 1998
TITLE: Tricyclic retinoids, methods for their production and use
INVENTOR: Chan Kou Hwang, Boulder, CO
Steven K. White, San Diego, CA
Youssef L. Bennani, La Jolla, CA
Stacie S. Canan Koch, San Diego, CA
Beth Ann Badea, San Diego, CA
Jonathan J. Hebert, Mission Viejo, CA
Alex M. Nadzan, San Diego, CA
ASSIGNEE: Ligand Pharmaceuticals, Inc., San Diego, CA (U.S. corp.)
APPL-NO: 08/472,127
DATE FILED: Jun. 7, 1995
ART-UNIT: 168
PRIM-EXMR: Ponnathapura Achutamurthy
LEGAL-REP: William L. Respess, J. Scott Elmer

US PAT NO: 5,770,378 [IMAGE AVAILABLE] L2: 15 of 28

ABSTRACT:
Tricyclic retinoids having activity for retinoic acid receptors and/or retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such tricyclic retinoid compounds and methods for their therapeutic use.

US PAT NO: 5,763,223 [IMAGE AVAILABLE] L2: 16 of 28
DATE ISSUED: Jun. 9, 1998
TITLE: DNA encoding a cytokine that induces apoptosis
INVENTOR: Steven R. Wiley, Seattle, WA
Raymond G. Goodwin, Seattle, WA
ASSIGNEE: Immunex Corporation, Seattle, WA (U.S. corp.)
APPL-NO: 08/670,354
DATE FILED: Jun. 25, 1996
ART-UNIT: 182
PRIM-EXMR: John Ulm
ASST-EXMR: Prema Mertz
LEGAL-REP: Kathryn A. Anderson

US PAT NO: 5,763,223 [IMAGE AVAILABLE] L2: 16 of 28

ABSTRACT:
A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.

US PAT NO: 5,763,220 [IMAGE AVAILABLE] L2: 17 of 28
DATE ISSUED: Jun. 9, 1998
TITLE: Human apoptosis-related calcium-binding protein
INVENTOR: Jennifer L. Hillman, San Jose, CA
Surya K. Goli, Sunnyvale, CA
ASSIGNEE: Incyte Pharmaceuticals, Inc., Palo Alto, CA (U.S. corp.)
APPL-NO: 08/766,605
DATE FILED: Dec. 12, 1996
ART-UNIT: 184
PRIM-EXMR: Robert A. Wax
ASST-EXMR: Garbrile E. Bugaisky
LEGAL-REP: Lucy J. Billings

US PAT NO: 5,763,220 [IMAGE AVAILABLE] L2: 17 of 28

ABSTRACT:
The present invention provides a human apoptosis-related calcium-binding protein (HARC) and polynucleotides which identify and encode HARC. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HARC and a method for producing HARC. The invention also provides for agonists, antibodies, or antagonists specifically binding HARC, and their use, in the prevention and treatment of diseases associated with expression of HARC. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HARC for the treatment of diseases associated with the expression of HARC. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HARC.

US PAT NO: 5,759,536 [IMAGE AVAILABLE] L2: 18 of 28
DATE ISSUED: Jun. 2, 1998
TITLE: Use of fas ligand to supress T-lymphocyte-mediated immune responses
INVENTOR: Donald Bellgrau, Denver, CO
Richard C. Duke, Denver, CO
SIGNEE: University Technology Corporation, Boulder, CO (U.S. corp.)
APPL-NO: 08/378,507
DATE FILED: Jan. 26, 1995
ART-UNIT: 189
PRIM-EXMR: Bruce R. Campbell
LEGAL-REP: Sheridan & Ross, P.C.

US PAT NO: 5,759,536 [IMAGE AVAILABLE] L2: 18 of 28

ABSTRACT:
A method for inhibiting T-lymphocyte-mediated immune responses, including those directed against autologous and/or heterologous tissues, e.g., by a recipient mammal of a transplanted tissue, said method comprising providing the recipient mammal with **Fas ligand**. The **Fas ligand** may be provided to the recipient mammal by a variety of means, including by pump implantation or by transplantation of transgenic tissue expressing **Fas ligand**. Also provided is a method for diagnostic use of **Fas ligand** expression in improving transplantation success.

US PAT NO: 5,756,086 [IMAGE AVAILABLE] L2: 19 of 28
DATE ISSUED: May 26, 1998
TITLE: Adenoviruses having modified fiber proteins
INVENTOR: Alan McClelland, Gaithersburg, MD
Susan C. Stevenson, Frederick, MD
ASSIGNEE: Genetic Therapy, Inc., Gaithersburg, MD (U.S. corp.)
APPL-NO: 08/591,492
DATE FILED: Feb. 6, 1996
ART-UNIT: 185
PRIM-EXMR: Johnny F. Railey, II
LEGAL-REP: Elliot M. Olstein, Raymond J. Lillie

US PAT NO: 5,756,086 [IMAGE AVAILABLE] L2: 19 of 28

ABSTRACT:

An adenovirus wherein the adenovirus fiber protein includes a ligand which is specific for a receptor located on a desired cell type. The adenovirus may have at least a portion of the adenovirus fiber protein removed and replaced with a ligand which is specific for a receptor located on a desired cell type, or the adenovirus may include a fusion protein of the adenovirus fiber protein and the ligand. Such an adenovirus may also include a gene(s) encoding a therapeutic agent(s) and may be "targeted" in order to deliver such gene(s) to a desired cell type.

US PAT NO: 5,753,446 [IMAGE AVAILABLE] L2: 20 of 28
DATE ISSUED: May 19, 1998
TITLE: Mitogen ERK kinase kinase (MEKK) assay
INVENTOR: Gary L. Johnson, Boulder, CO
ASSIGNEE: National Jewish Center for Immunology & Respiratory Medicine, Denver, CO (U.S. corp.)
APPL-NO: 08/472,934
DATE FILED: Jun. 6, 1995
ART-UNIT: 182
PRIM-EXMR: Sephen Walsh
ASST-EXMR: Kenneth A. Sorensen
LEGAL-REP: Giulio A. DeConti, Jr., Catherine J. Kara

US PAT NO: 5,753,446 [IMAGE AVAILABLE] L2: 20 of 28

ABSTRACT:
The present invention relates to isolated MEKK proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods useful for identifying compounds capable of specifically regulating signal transduction in cells expressing MEKK protein.

US PAT NO: 5,750,653 [IMAGE AVAILABLE] L2: 21 of 28
DATE ISSUED: May 12, 1998
TITLE: Protein, FAF1, which potentiates Fas-mediated apoptosis and uses thereof
INVENTOR: Keting Chu, Burlingame, CA
Lewis T. Williams, Tiburon, CA
ASSIGNEE: The Regents of the University of California, Oakland, CA (U.S. corp.)
APPL-NO: 08/477,476
DATE FILED: Jun. 7, 1995
ART-UNIT: 182
PRIM-EXMR: Stephen Walsh
ASST-EXMR: Daryl A. Basham
LEGAL-REP: Townsend and Townsend and Crew LLP

US PAT NO: 5,750,653 [IMAGE AVAILABLE] L2: 21 of 28

ABSTRACT:
The present invention identifies a novel, Fas-associated factor 1 termed FAF1 which potentiates Fas-induced cell killing. The invention provides FAF1 nucleic acid and polypeptide compositions as well as methods of using these compositions in the therapeutic treatment of diseases resulting from dysregulation in apoptosis. Also provided are cells carrying and expressing the nucleic acid compositions and methods of using these cells to screen for agonists and antagonists of Fas-mediated apoptosis. Methods of isolating FAF1-interacting proteins are disclosed.

US PAT NO: 5,747,245 [IMAGE AVAILABLE] L2: 22 of 28
DATE ISSUED: May 5, 1998
TITLE: Nucleic acids encoding Fas associated proteins and screening assays using same
INVENTOR: John C. Reed, Carlsbad, CA
Takaaki Sato, San Diego, CA
ASSIGNEE: La Jolla Cancer Research Foundation, La Jolla, CA (U.S. corp.)
APPL-NO: 08/259,514
DATE FILED: Jun. 14, 1994
ART-UNIT: 187
PRIM-EXMR: Stephanie W. Zitomer
ASST-EXMR: Dianne Rees

US PAT NO: 5,747,245 [IMAGE AVAILABLE] L2: 22 of 28

ABSTRACT:
The present invention provides mammalian protein tyrosine phosphatases, human PTP-BAS type 4, human PTP-BAS type 5a and mouse PTP-BAS type 5b,
each of which is a Fas-associated protein (FAP), nucleic acid molecules encoding a PTP-BAS type 4 or a PTP-BAS type 5 and antibodies specific for a PTP-BAS type 4 or for a PTP-BAS type 5. The invention also provides methods for identifying FAP's, which can associate with Fas and can modulate apoptosis. The invention also provides screening assays for identifying an agent that can effectively alter the association of a FAP with Fas and, therefore, can increase or decrease the level of apoptosis in a cell. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a PTP-BAS or an antisense nucleotide sequence, which is complementary to a portion of a nucleic acid molecule encoding a PTP-BAS. The invention also provides a method of using a reagent that can specifically bind to a FAP to diagnose a pathology that is characterized by an increased or decreased level of apoptosis in a cell. The invention also provides methods of modulating apoptosis in a cell by contacting the cell with an agent that effectively alters the association of a FAP and Fas in a cell or alters the activity of a FAP in a cell.

US PAT NO: 5,712,262 [IMAGE AVAILABLE] L2: 23 of 28
DATE ISSUED: Jan. 27, 1998
TITLE: Use of sphingosine-1-phosphate to suppress programmed cell death
INVENTOR: Sarah Spiegel, 6343 Linway Terr., McLean, VA 22101
APPL-NO: 08/754,323
DATE FILED: Nov. 21, 1996
ART-UNIT: 125
PRIM-EXMR: Phyllis G. Spivack
LEGAL-REP: Glenna Hendricks, Carol Carr

US PAT NO: 5,712,262 [IMAGE AVAILABLE] L2: 23 of 28

ABSTRACT:
Admisistration of sphingosine-1-phosphate to retard apoptosis in degenerative diseases as neurodegenerative disease, ischemic stroke and aging is disclosed wherein slowing of the process of programmed cell death is useful as a means to slow the degenerative process in patients suffering from these diseases.

US PAT NO: 5,712,115 [IMAGE AVAILABLE] L2: 24 of 28
DATE ISSUED: Jan. 27, 1998
TITLE: Human cell death-associated protein
INVENTOR: Phillip R. Hawkins, Mountain View, CA
Scott Michael Braxton, San Mateo, CA
Lynn E. Murry, Portola Valley, CA
ASSIGNEE: Incyte Pharmaceuticals, Inc., Palo Alto, CA (U.S. corp.)
APPL-NO: 08/618,164
DATE FILED: Mar. 19, 1996
ART-UNIT: 186
PRIM-EXMR: Christina Y. Chan
ASST-EXMR: Emma Cech
LEGAL-REP: Lucy J. Billings, Barbara J. Luther

US PAT NO: 5,712,115 [IMAGE AVAILABLE] L2: 24 of 28

ABSTRACT:
The present invention provides a polynucleotide which identifies and encodes a human cell death-associated protein (cdap) which was isolated from a rheumatoid synovium library. The invention provides for genetically engineered expression vectors and host cells comprising a nucleic acid sequence encoding CDAP. The invention also provides for the therapeutic use of purified CDAP, cdap or its antisense molecules, or CDAP inhibitors in pharmaceutical compositions and for treatment of conditions or diseases associated with expression of CDAP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, or fragments thereof, or antibodies which specifically bind to the polypeptide.

US PAT NO: 5,663,070 [IMAGE AVAILABLE] L2: 25 of 28
DATE ISSUED: Sep. 2, 1997
TITLE: Recombinant production of a soluble splice variant of the Fas (Apo-1) antigen, fas TM
INVENTOR: Philip J. Barr, Berkeley, CA
John P. Shapiro, Albany, CA
Michael C. Kiefer, Clayton, CA
ASSIGNEE: LXR Biotechnology Inc., Richmond, CA (U.S. corp.)
APPL-NO: 08/152,443
DATE FILED: Nov. 15, 1993
ART-UNIT: 182
PRIM-EXMR: David L. Fitzgerald
LEGAL-REP: Morrison & Foerster

US PAT NO: 5,663,070 [IMAGE AVAILABLE] L2: 25 of 28

ABSTRACT:
The invention provides soluble forms of the Fas (Apo-1) protein

comprising both the intracellular and extracellular domains of the full-length polypeptide. Exemplified is a naturally-occurring splice variant of the Fas gene, Fas.DELTA.TM, which lacks the transmembrane domain of the native antigen. DNA encoding the protein, cells expressing the recombinant DNA, and methods of using the protein and DNA are also provided.

US PAT NO: 5,652,210 [IMAGE AVAILABLE] L2: 26 of 28
DATE ISSUED: Jul. 29, 1997
TITLE: Soluble splice variant of the Fas (APO-1) antigen, Fas.DELTA.TM
INVENTOR: Philip J. Barr, Berkeley, CA
John P. Shapiro, Albany, CA
Michael C. Kiefer, Clayton, CA
ASSIGNEE: LXR Biotechnology, Inc., Richmond, CA (U.S. corp.)
APPL-NO: 08/444,231
DATE FILED: May 18, 1995
ART-UNIT: 182
PRIM-EXMR: David L. Fitzgerald
LEGAL-REP: Morrison & Foerster

S PAT NO: 5,652,210 [IMAGE AVAILABLE] L2: 26 of 28

ABSTRACT:
The invention provides soluble forms of the Fas (Apo-1) protein comprising both the intracellular and extracellular domains of the full-length polypeptide. Exemplified is a naturally-occurring splice variant of the Fas gene, Fas.DELTA.TM, which lacks the transmembrane domain of the native antigen. DNA encoding the protein, cells expressing the recombinant DNA, and methods of using the protein and DNA are also provided.

US PAT NO: 5,632,994 [IMAGE AVAILABLE] L2: 27 of 28
DATE ISSUED: May 27, 1997
TITLE: Fas associated proteins
INVENTOR: John C. Reed, Carlsbad, CA
Takaaki Sato, San Diego, CA
ASSIGNEE: La Jolla Cancer Research Foundation, La Jolla, CA (U.S. corp.)
APPL-NO: 08/410,804
DATE FILED: Mar. 27, 1995
ART-UNIT: 187
PRIM-EXMR: Stephanie W. Zitomer
ASST-EXMR: Dianne Rees
LEGAL-REP: Campbell and Flores

US PAT NO: 5,632,994 [IMAGE AVAILABLE] L2: 27 of 28

BSTRACT:
e present invention provides mammalian protein tyrosine phosphatases, human PTP-BAS type 4, human PTP-BAS type 5a and mouse PTP-BAS type 5b,
each of which is a Fas-associated protein (FAP), nucleic acid molecules encoding a PTP-BAS type 4 or a PTP-BAS type 5 and antibodies specific for a PTP-BAS type 4 or for a PTP-BAS type 5. The invention also provides methods for identifying FAP's, which can associate with Fas and can modulate apoptosis. The invention also provides screening assays for identifying an agent that can effectively alter the association of a FAP with Fas and, therefore, can increase or decrease the level of apoptosis in a cell. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a PTP-BAS or fragment of a PTP-BAS or an antisense nucleotide sequence, which is complementary to a portion of a nucleic acid molecule encoding a PTP-BAS. The invention also provides a method of using a reagent that can specifically bind to a FAP to diagnose a pathology that is characterized by an increased or decreased level of apoptosis in a cell. The invention also provides methods of modulating apoptosis in a cell by contacting the cell with an agent that effectively alters the association of a FAP and Fas in a cell or alters the activity of a FAP in a cell.

US PAT NO: 5,620,889 [IMAGE AVAILABLE] L2: 28 of 28
DATE ISSUED: Apr. 15, 1997
TITLE: Human anti-Fas IgG1 monoclonal antibodies
INVENTOR: David H. Lynch, Bainbridge Island, WA
Mark R. Alderson, Bainbridge Island, WA
ASSIGNEE: Immunex Corporation, Seattle, WA (U.S. corp.)
APPL-NO: 08/322,805
DATE FILED: Oct. 13, 1994
ART-UNIT: 186
PRIM-EXMR: Susan A. Loring

US PAT NO: 5,620,889 [IMAGE AVAILABLE] L2: 28 of 28

ABSTRACT:
The present invention provides a panel of monoclonal antibodies and binding proteins which specifically bind to human Fas antigen. Some of the antibodies and binding proteins are capable of stimulating T cell proliferation, inhibiting binding of anti-Fas CH-11 monoclonal antibody to cells expressing Fas antigen, blocking anti-Fas CH-11 monoclonal antibody-mediated lysis of cells, and blocking Fas ligand-mediated lysis of cells. The invention also provides for therapeutic compositions comprising the monoclonal antibodies.

=> d his

(FILE 'USPAT' ENTERED AT 15:02:01 ON 25 MAR 1999)
E GOODWIN, RAYMOND/IN
L1 23 S E1 OR E3 OR E4
L2 28 S FAS(W)LIGAND
L3 1 S L1 AND L2

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

U.S. Patent & Trademark Office LOGOFF AT 15:23:04 ON 25 MAR 1999